Clascoterone vs Minoxidil
FDA Approved vs FDA Approved
synergistic Researched · 95% Minoxidil promotes hair growth via vasodilation and potassium channel activation, a mechanism entirely independent of androgen signaling. Combining clascoterone (which blocks androgen receptor activation at the follicle) with minoxidil (which stimulates follicular blood flow and growth signaling) addresses hair loss from two distinct pathways. The two topicals should be applied at separate times to ensure proper absorption of each.
Molecular Data
Clascoterone Minoxidil
Weight 388.54 Da 209.25 Da
Half-life Short topical (local action; rapidly metabolized to cortexolone) ~4 hours (oral); topical effects persist significantly longer due to local tissue retention
Type Steroidal androgen receptor inhibitor Synthetic pyrimidine derivative (6-amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidinopyrimidine)
Key Benefits
Clascoterone
01 First-in-class topical androgen receptor inhibitor with FDA approval for acne
02 Blocks androgen action locally at the sebaceous gland and hair follicle without systemic hormonal effects
03 Suitable for both men and women, unlike systemic anti-androgens
04 Rapidly metabolized to inactive cortexolone, limiting systemic exposure
05 No clinically meaningful effects on systemic testosterone, DHT, or gonadotropin levels
06 Addresses the root androgen-driven pathology of both acne and androgenetic alopecia
Minoxidil
01 FDA-approved for androgenetic alopecia with decades of clinical evidence
02 Stimulates new hair growth and increases hair follicle size independent of androgen pathways
03 Available over the counter as a topical treatment without a prescription
04 Effective in both men and women for pattern hair loss
05 Low-dose oral formulation offers a convenient once-daily alternative to twice-daily topical application
06 Synergistic with finasteride and dutasteride for a multi-mechanism approach to hair loss
07 Extends the anagen (growth) phase and shortens the telogen (resting) phase of the hair cycle
Side Effects
Clascoterone
Application site irritation, redness, or dryness
Pruritus (itching) at the application site
Contact dermatitis in sensitive individuals
Minoxidil
Scalp irritation, dryness, or flaking (topical, especially solution formulations containing propylene glycol)
Initial shedding phase during the first 1-3 months of treatment
Hypertrichosis (unwanted facial and body hair growth, more common with oral administration)
Fluid retention and mild peripheral edema (oral)
Mild dizziness or lightheadedness upon standing (oral, due to vasodilation)
Contraindications
Known hypersensitivity to clascoterone or any component of the formulation
Women who are pregnant or planning to become pregnant (anti-androgens carry theoretical teratogenic risk)
Women who are breastfeeding (safety not established)
Active skin infections at the intended application site
Known hypersensitivity to minoxidil or any component of the formulation
Pheochromocytoma (minoxidil may stimulate catecholamine release)
Significant cardiovascular disease, including history of pericardial effusion or congestive heart failure
Concurrent use of potent antihypertensive medications without physician supervision (risk of additive hypotension)
Pregnancy and breastfeeding (Category C; oral minoxidil has shown evidence of fetal harm in animal studies)
Research Evidence
Clascoterone Minoxidil
Status FDA Approved FDA Approved
References 4 studies 5 studies
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.